Discovery of Potent and Selective Antibody–Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization

[Image: see text] Targeted antimitotic agents are a promising class of anticancer therapies. Herein, we describe the development of a potent and selective antimitotic Eg5 inhibitor based antibody–drug conjugate (ADC). Preliminary studies were performed using proprietary Eg5 inhibitors which were con...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:ACS Med Chem Lett
Glavni autori: Karpov, Alexei S., Nieto-Oberhuber, Cristina M., Abrams, Tinya, Beng-Louka, Edwige, Blanco, Enrique, Chamoin, Sylvie, Chene, Patrick, Dacquignies, Isabelle, Daniel, Dylan, Dillon, Michael P., Doumampouom-Metoul, Lionel, Drosos, Nikolaos, Fedoseev, Pavel, Furegati, Markus, Granda, Brian, Grotzfeld, Robert M., Hess Clark, Suzanna, Joly, Emilie, Jones, Darryl, Lacaud-Baumlin, Marion, Lagasse-Guerro, Stephanie, Lorenzana, Edward G., Mallet, William, Martyniuk, Piotr, Marzinzik, Andreas L., Mesrouze, Yannick, Nocito, Sandro, Oei, Yoko, Perruccio, Francesca, Piizzi, Grazia, Richard, Etienne, Rudewicz, Patrick J., Schindler, Patrick, Velay, Mélanie, Venstrom, Kristine, Wang, Peiyin, Zurini, Mauro, Lafrance, Marc
Format: Artigo
Jezik:Inglês
Izdano: American Chemical Society 2019
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6912867/
https://ncbi.nlm.nih.gov/pubmed/31857845
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.9b00468
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items